Cargando…

Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?

γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasom...

Descripción completa

Detalles Bibliográficos
Autores principales: Clementz, Anthony G, Osipo, Clodia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790851/
https://www.ncbi.nlm.nih.gov/pubmed/19849815
http://dx.doi.org/10.1186/bcr2407
_version_ 1782175138948579328
author Clementz, Anthony G
Osipo, Clodia
author_facet Clementz, Anthony G
Osipo, Clodia
author_sort Clementz, Anthony G
collection PubMed
description γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, γ-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han and colleagues pose two critical questions: Is the level of proteasomal activity in breast tumors the driving force for growth? What does the Notch pathway contribute to this growth?
format Text
id pubmed-2790851
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27908512009-12-10 Notch versus the proteasome: what is the target of γ-secretase inhibitor-I? Clementz, Anthony G Osipo, Clodia Breast Cancer Res Editorial γ-Secretase inhibitors are new anti-cancer agents targeting Notch signaling. Their specificity for Notch is as yet unclear. Han and colleagues investigated the effects of Z-LeuLeuNleu-CHO on growth of breast cancer cells. The results demonstrated a reduction in cell viability primarily via proteasome inhibition independent of Notch activity. Currently, γ-secretase inhibitors in clinical trials are structurally distinct from Z-LeuLeuNleu-CHO. Their effects on the proteasome are yet to be determined. However, findings from Han and colleagues pose two critical questions: Is the level of proteasomal activity in breast tumors the driving force for growth? What does the Notch pathway contribute to this growth? BioMed Central 2009 2009-10-15 /pmc/articles/PMC2790851/ /pubmed/19849815 http://dx.doi.org/10.1186/bcr2407 Text en Copyright ©2009 BioMed Central Ltd
spellingShingle Editorial
Clementz, Anthony G
Osipo, Clodia
Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
title Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
title_full Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
title_fullStr Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
title_full_unstemmed Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
title_short Notch versus the proteasome: what is the target of γ-secretase inhibitor-I?
title_sort notch versus the proteasome: what is the target of γ-secretase inhibitor-i?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790851/
https://www.ncbi.nlm.nih.gov/pubmed/19849815
http://dx.doi.org/10.1186/bcr2407
work_keys_str_mv AT clementzanthonyg notchversustheproteasomewhatisthetargetofgsecretaseinhibitori
AT osipoclodia notchversustheproteasomewhatisthetargetofgsecretaseinhibitori